Terms: = Lymphoma AND EML4, ENSG00000143924, 27436 AND Prognosis
49 results:
1. Longitudinal plasma proteomic profiling of eml4-ALK positive lung cancer receiving ALK-TKIs therapy.
Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
[TBL] [Abstract] [Full Text] [Related]
2. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-eml4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract] [Full Text] [Related]
3. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
4. eml4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract] [Full Text] [Related]
5. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract] [Full Text] [Related]
6. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract] [Full Text] [Related]
7. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
[TBL] [Abstract] [Full Text] [Related]
8. [Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and pathological analysis].
Di SH; Wang XT; Xia QY; Lu ZF; Ma HH; Zhang RS; Wang X; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):28-32. PubMed ID: 34979750
[No Abstract] [Full Text] [Related]
9. Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study.
Jiang F; Wang C; Yang P; Sun P; Liu J
World J Surg Oncol; 2021 Sep; 19(1):278. PubMed ID: 34530849
[TBL] [Abstract] [Full Text] [Related]
10. Coexistence of a secondary STRN-ALK, eml4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract] [Full Text] [Related]
11. Observed progression from melanosis with melanocyte hyperplasia to sinonasal melanoma with distant metastasis and a unique genetic rearrangement.
Salari B; Duncan LM; Lennerz JK; Holbrook EH; Emerick KS; Foreman RK
J Cutan Pathol; 2021 Jul; 48(7):948-953. PubMed ID: 33694261
[TBL] [Abstract] [Full Text] [Related]
12. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract] [Full Text] [Related]
13. Treatment Sequencing for Anaplastic lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
Kauffmann-Guerrero D; Kahnert K; Huber RM
Drugs; 2021 Jan; 81(1):87-100. PubMed ID: 33226527
[TBL] [Abstract] [Full Text] [Related]
14. [Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].
Wang S; Shi Y; Han X
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):1014-1022. PubMed ID: 33203201
[TBL] [Abstract] [Full Text] [Related]
15. Distribution of eml4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Tao H; Shi L; Zhou A; Li H; Gai F; Huang Z; Che N; Liu Z
Lung Cancer; 2020 Nov; 149():154-161. PubMed ID: 33017727
[TBL] [Abstract] [Full Text] [Related]
16. 68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report.
Tanriverdi O; Tarimer ML; Pak CD; Uylas S; Alkan A; Celik OI; Kilic RM; Zeybek A
J Oncol Pharm Pract; 2021 Jun; 27(4):984-989. PubMed ID: 32830600
[TBL] [Abstract] [Full Text] [Related]
17. An ALK-positive lung adenocarcinoma with gastric and skin metastasis: a case report and literature review.
Duan X; Zhao X; Wang S
Ann Palliat Med; 2021 May; 10(5):5797-5807. PubMed ID: 32819126
[TBL] [Abstract] [Full Text] [Related]
18. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
Sakai K; Kuramoto J; Kojima A; Nishimura H; Kuwabara Y; Toda M; Kobayashi Y; Kikuchi S; Hirata Y; Mikami-Saito Y; Mikami S; Kyoyama H; Moriyama G; Gemma A; Uematsu K
Int J Clin Oncol; 2019 Dec; 24(12):1549-1557. PubMed ID: 31452019
[TBL] [Abstract] [Full Text] [Related]
19. Malignant Pleural Effusion and Its Current Management: A Review.
Skok K; Hladnik G; Grm A; Crnjac A
Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31443309
[TBL] [Abstract] [Full Text] [Related]
20. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract] [Full Text] [Related]
[Next]